Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
33.6
% (year-on-year change in operating income)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPNet Sales56,082Millions of yenYear on year +14.8%Progress 51.9%
Operating profit10,836Millions of yenYear on year +33.6%Progress 52.9%
Ordinary income11,572Millions of yenYear on year +29.9%Progress 52.4%
Net income attributable to owners of the parent8,016Millions of yenYear on year +18.7%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥65.98
Financial position at period-end
Total assets177,068Millions of yen
of which net assets 132,993 Millions of yenEquity ratio 75.1%vs. prior year-end -1.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+6,344
Investment-3,895
Financials-7,007
Net change-4,558
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period44,276 Millions of yen
Segment revenueBasic Chemicals 22,691 Millions of yen (YoY +11.8%), Functional Chemicals 16,204 Millions of yen (YoY +19.2%), Healthcare 8,431 Millions of yen (YoY +25.7%), Trading and Other 8,755 Millions of yen (YoY +6.5%)
Segment profitBasic Chemicals 3,005 Millions of yen, Functional Chemicals 4,013 Millions of yen, Healthcare 3,979 Millions of yen, Trading and Other 501 Millions of yen
Regional sales32,245 Millions of yen, 8,376 Millions of yen, 7,860 Millions of yen, 4,976 Millions of yen, 2,623 Millions of yen
Outlook and shareholder returns
Full-year earnings forecast
Net Sales108,000 Millions of yen (YoY +8.0%)
Operating profit20,500 Millions of yen (YoY +16.2%)
Ordinary income22,100 Millions of yen (YoY +12.7%)
Profit attributable to owners of the parent14,800 Millions of yen (YoY -4.3%)
Revision to Earnings ForecastNo
Annual Dividend Forecast28 Yen → 32 Yen（+14.3%）
Factors Behind Changes in Business Performance
Price revisions, higher sales volumes, expanding demand for pharmaceutical purification materials and other products, increased sales of active pharmaceutical ingredients and intermediates, and higher sales of inorganic chemicals and glass fiber.
Disclosure regarding the going concern assumption
Not applicable
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name Not applicable
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets 132 Millions of yen / Extraordinary loss Loss on disposal of non-current assets 180 Millions of yen
Depreciation and amortization2,394 Millions of yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End133,660,085 Shares
Treasury Shares at Period-End13,394,413 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | 56,082 Millions of yen (YoY +14.8%) |
| Operating profit | 10,836 Millions of yen (YoY +33.6%) |
| Ordinary income | 11,572 Millions of yen (YoY +29.9%) |
| Profit attributable to owners of the parent | 8,016 Millions of yen (YoY +18.7%) |
| Net income per share | ¥65.98 |
| Equity ratio | End of the current fiscal period 75.1 / End of previous period 76.2 |
| Total assets | 177,068 Millions of yen |
| Net assets | 132,993 Millions of yen |
| Cash flows from operating activities | 6,344 Millions of yen |
| Cash flows from investing activities | -3,895 Millions of yen |
| Cash flows from financing activities | -7,007 Millions of yen |
| Cash and cash equivalents at end of period | 44,276 Millions of yen |
| Full-year earnings forecast | Net Sales 108,000 Millions of yen (YoY +8.0%) / Operating profit 20,500 Millions of yen (YoY +16.2%) / Ordinary income 22,100 Millions of yen (YoY +12.7%) / Profit attributable to owners of the parent 14,800 Millions of yen (YoY -4.3%) |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | 28 Yen → 32 Yen（+14.3%） |
| Segment revenue | Basic Chemicals 22,691 Millions of yen (YoY +11.8%), Functional Chemicals 16,204 Millions of yen (YoY +19.2%), Healthcare 8,431 Millions of yen (YoY +25.7%), Trading and Other 8,755 Millions of yen (YoY +6.5%) |
| Segment profit | Basic Chemicals 3,005 Millions of yen, Functional Chemicals 4,013 Millions of yen, Healthcare 3,979 Millions of yen, Trading and Other 501 Millions of yen |
| Regional sales | 32,245 Millions of yen, 8,376 Millions of yen, 7,860 Millions of yen, 4,976 Millions of yen, 2,623 Millions of yen |
| Depreciation and amortization | 2,394 Millions of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets 132 Millions of yen / Extraordinary loss Loss on disposal of non-current assets 180 Millions of yen |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 133,660,085 Shares |
| Treasury Shares at Period-End | 13,394,413 Shares |
| Factors Behind Changes in Business Performance | Price revisions, higher sales volumes, expanding demand for pharmaceutical purification materials and other products, increased sales of active pharmaceutical ingredients and intermediates, and higher sales of inorganic chemicals and glass fiber. |
Items this document does not state (6)
Operating MarginPayout ratioShareholder Return PolicyOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased due to price revisions and higher sales volumes, expanding demand in healthcare fields such as pharmaceutical purification materials, increased sales of active pharmaceutical ingredients and intermediates, and higher sales of inorganic chemicals and glass fiber. In response to rising raw material and fuel prices, the company revised product prices to minimize the impact.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.